vhl alliance

Be Part of Finding a New Treatment

MD Anderson Cancer Center is the first of a multicenter clinical trial for PT2977 (Peloton) to open. PT2977 is a promising HIF2 inhibitor for VHL-associated kidney tumors showing minimal side effects.

Contact Christine Robichaux at Robichaux@mdanderson.org, 713.794.4077.

(ClinicalTrials.gov Identifier: NCT03401788)



Read the entire article